Cara Therapeutics to Present at the Jefferies Healthcare Conference
May 25 2021 - 7:00AM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company focused on developing and commercializing new chemical
entities designed to alleviate pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that Derek
Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will
participate in a fireside chat at the Jefferies Healthcare
Conference on Tuesday, June 1, 2021 at 11:00 a.m. ET.
A live webcast of the presentation can be
accessed under "Events & Presentations" in the News &
Investors section of the Company's website
at www.CaraTherapeutics.com. An archived webcast recording
will be available on the Cara website for approximately 30
days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral KORs. Cara is developing a novel and
proprietary class of product candidates, led by KORSUVA
(CR845/difelikefalin), a first-in-class KOR agonist that targets
KORs located in the peripheral nervous system and on immune cells.
In the Company’s KALM™-1 and KALM-2 Phase 3 trials and two Phase 2
trials, KORSUVA Injection has demonstrated statistically
significant reductions in itch intensity and concomitant
improvement in pruritus-related quality of life measures in
hemodialysis patients with moderate-to-severe CKD-aP. The FDA has
accepted and granted Priority Review for the NDA for KORSUVA
(difelikefalin) Injection for the treatment of moderate-to-severe
pruritus in hemodialysis patients. The PDUFA target action date for
KORSUVA is August 23, 2021. Oral KORSUVA has completed Phase 2
trials for the treatment of pruritus in patients with CKD and AD
and is currently in Phase 2 trials in PBC and NP patients with
moderate-to-severe pruritus.
The FDA has conditionally accepted KORSUVA as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
MEDIA CONTACT:Claire LaCagnina6
Degrees315-765-1462clacagnina@6degreespr.com
INVESTOR CONTACT:Janhavi MohiteStern Investor
Relations, Inc.212-362-1200janhavi.mohite@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024